Hepatic and intestinal first-pass effects of oltipraz in rats
β Scribed by Soo K. Bae; Jin W. Kim; Young H. Kim; Yoon G. Kim; Sang G. Kim; Myung G. Lee
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 82 KB
- Volume
- 26
- Category
- Article
- ISSN
- 0142-2782
- DOI
- 10.1002/bdd.439
No coin nor oath required. For personal study only.
β¦ Synopsis
It was reported that the mean value of the extent of absolute oral bioavailability (F) of oltipraz at a dose of 20 mg/kg was 41.2% and only 2.68% of the oral dose was unabsorbed from the gastrointestinal tract in rats. Hence, the low F in rats could be due to considerable first-pass (gastric, intestinal and hepatic) effects. Hence, the first-pass effects of oltipraz were measured after intravenous, intraportal, intragastric and intraduodenal administration of the drug at a dose of 20 mg/kg to rats. The total area under the plasma concentration-time curve from time zero to time infinity (AUC) values between intragastric and intraduodenal administration (213 and 212 mg min/ ml) in rats were almost similar, but the values were significantly smaller than that after intraportal administration (316 mg min/ml) in rats, indicating that gastric first-pass effect was almost negligible (due to negligible absorption of oltipraz from rat stomach), but the intestinal first-pass effect of oltipraz was considerable, approximately 32% of the oral dose. The hepatic first-pass effect of oltipraz was approximately 40% based on AUC values between intravenous and intraportal administration (319 versus 536 mg min/ml). Since approximately 65% of the oral oltipraz was absorbed into the portal vein, the value of 40% was equivalent to 25% of the oral dose. The low F of oltipraz in rats was mainly due to considerable hepatic and intestinal first-pass effects. Copyright
π SIMILAR VOLUMES
Studies were designed to allow an in vivo estimation of the hepatic extraction ratio and to test the hypothesis that the pharmacokinetic parameters of (-)-CBV are significantly different during anesthesia. (-)-CBV was administered as an IV bolus followed by IV infusion into either the portal (n = 3)
## Abstract The pharmacokinetics of mirodenafil and its two metabolites, SK3541 and SK3544, after intravenous (5, 10, 20 and 50βmg/kg) and oral (10, 20 and 50βmg/kg) administration of mirodenafil, and the firstβpass effect of mirodenafil after intravenous, oral, intraportal, intragastric and intrad
To assess avoidance of hepatic first-pass effect of drugs, we undertook in situ experiments using rectal administration of lidocaine in the rabbit. We also employed in situ duodenal route to estimate first-pass metabolism across the gastrointestinal mucosa. Rabbits were administered lidocaine HCl in
The pharmacokinetics of YH1885 were evaluated after intravenous (iv) and oral administrations of the drug to rats and dogs. The reason for the low extent of bioavailability (F) of YH1885 after oral administration of the drug to rats and the absorption of the drug from various rat gastrointestinal (G
## Abstract The contribution of gastrointestinal tract (GIT), liver, and lung towards the firstβpass metabolism of acetaminophen was examined using 3βweekβold, 10βweekβold and 1βyearβold rats after administration of 30mgkg^β1^ doses by intraβarterial, intravenous, intraperitoneal, and oral routes.